A PYMNTS Company

US: NY declares victory in Alzheimer’s drug antitrust lawsuit

By  |  November 26, 2015

New York’s attorney general is dropping an antitrust lawsuit against a drug manufacturer after his office blocked what he alleged was an attempt to force Alzheimer’s patients to switch to a newer patented drug instead of cheaper generic alternatives.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Attorney General Eric Schneiderman and Allergan PLC said Wednesday that they have agreed to resolve the lawsuit filed over the company’s plans to withdraw Namenda, a popular Alzheimer’s treatment, a few months before lower-cost generic drugs became available.

    Schneiderman’s office had argued the move was timed to force patients onto a new patented drug Namenda XR instead of the generics.

    A federal judge agreed last year, requiring Allergan to continue distributing the older drug until summer 2015, when generic medications entered the market.

    “Our lawsuit prevented Allergan from pursuing its plan to block competition, thus preserving patient choice for hundreds of thousands of Alzheimer’s patients, and protecting the public from bearing hundreds of millions’ of dollars in unnecessary drug costs,” Schneiderman said in a statement announcing the resolution of the legal challenge.

    The Dublin-based Allergan, previously known as Actavis, confirmed the settlement. The company has agreed to pay $172,000 to cover some of the state’s legal fees.

    Full content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.